NODARI, Savina
 Distribuzione geografica
Continente #
NA - Nord America 26.944
AS - Asia 19.190
EU - Europa 16.930
SA - Sud America 3.828
AF - Africa 302
OC - Oceania 60
Continente sconosciuto - Info sul continente non disponibili 34
AN - Antartide 2
Totale 67.290
Nazione #
US - Stati Uniti d'America 26.361
CN - Cina 6.866
SG - Singapore 6.417
UA - Ucraina 5.276
IT - Italia 3.597
BR - Brasile 3.315
HK - Hong Kong 2.362
DE - Germania 2.170
FI - Finlandia 1.042
IN - India 1.009
GB - Regno Unito 994
TR - Turchia 869
PL - Polonia 817
IE - Irlanda 801
VN - Vietnam 735
RU - Federazione Russa 723
FR - Francia 672
SE - Svezia 342
CA - Canada 309
BD - Bangladesh 193
AR - Argentina 192
MX - Messico 183
IQ - Iraq 143
NL - Olanda 128
ZA - Sudafrica 85
JP - Giappone 84
ID - Indonesia 83
ES - Italia 82
SA - Arabia Saudita 81
EC - Ecuador 79
PK - Pakistan 74
CO - Colombia 72
BE - Belgio 59
AU - Australia 57
UZ - Uzbekistan 51
KE - Kenya 48
AT - Austria 46
PY - Paraguay 42
MA - Marocco 41
MU - Mauritius 41
VE - Venezuela 41
EG - Egitto 36
MY - Malesia 33
EU - Europa 31
CL - Cile 30
CH - Svizzera 27
NO - Norvegia 23
PE - Perù 23
UY - Uruguay 23
NP - Nepal 22
TN - Tunisia 22
CZ - Repubblica Ceca 19
AE - Emirati Arabi Uniti 18
JM - Giamaica 16
TT - Trinidad e Tobago 16
BG - Bulgaria 15
JO - Giordania 15
LT - Lituania 15
IL - Israele 14
PT - Portogallo 14
RO - Romania 14
KZ - Kazakistan 13
TW - Taiwan 13
IR - Iran 12
LB - Libano 12
OM - Oman 12
AZ - Azerbaigian 11
CR - Costa Rica 11
ET - Etiopia 11
AL - Albania 10
HN - Honduras 9
PA - Panama 9
BH - Bahrain 8
BO - Bolivia 8
TH - Thailandia 8
BA - Bosnia-Erzegovina 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
BB - Barbados 4
HU - Ungheria 4
KW - Kuwait 4
LK - Sri Lanka 4
MK - Macedonia 4
NI - Nicaragua 4
PH - Filippine 4
SV - El Salvador 4
AM - Armenia 3
BZ - Belize 3
DK - Danimarca 3
GR - Grecia 3
GT - Guatemala 3
HR - Croazia 3
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
AO - Angola 2
CY - Cipro 2
Totale 67.252
Città #
Jacksonville 3.833
Singapore 3.093
Hong Kong 2.349
Fairfield 1.971
Chandler 1.945
Woodbridge 1.700
Ashburn 1.583
Princeton 1.550
Nanjing 1.415
Beijing 1.371
Ann Arbor 1.244
Wilmington 1.217
Houston 1.196
Cambridge 1.045
Dublin 794
Warsaw 793
New York 763
Seattle 717
Istanbul 682
Nanchang 534
Los Angeles 480
Buffalo 390
Des Moines 379
Hebei 341
Shenyang 324
Milan 321
São Paulo 302
Moscow 301
The Dalles 279
Ho Chi Minh City 260
Changsha 256
Helsinki 249
Tianjin 236
Jiaxing 229
Rome 201
San Diego 185
Kunming 179
Dearborn 165
Verona 153
Redondo Beach 151
Jinan 148
Hanoi 144
Hangzhou 129
Brescia 123
San Francisco 122
Kocaeli 114
Rio de Janeiro 108
Shanghai 102
Newton 99
Mexico City 89
Toronto 88
Dallas 87
Munich 81
Boardman 79
Chicago 77
Zhengzhou 74
Belo Horizonte 68
Guangzhou 68
Lancaster 68
Tokyo 65
Brooklyn 64
London 63
Ningbo 61
Florence 58
Lanzhou 55
Vancouver 55
Naples 54
Santa Clara 53
Norwalk 52
Brasília 51
Changchun 51
Taizhou 49
Brussels 46
Tashkent 46
Council Bluffs 45
Baghdad 44
Porto Alegre 44
Curitiba 43
Nairobi 43
Salvador 40
Guarulhos 39
Atlanta 38
Napoli 38
Denver 37
Pune 37
Surrey 37
Campinas 36
Fuzhou 36
Johannesburg 35
Riyadh 35
Pamplona 34
Stockholm 34
Turku 34
Bologna 33
Da Nang 33
Dhaka 33
Goiânia 33
Montreal 33
Palermo 33
Catania 32
Totale 38.826
Nome #
Un caso di Sindrome di Bland-White-Garland: origine anomala dell’arteria coronaria sinistra dall’arteria polmonare. 715
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 695
Inodilatatori: perché e quali. 394
Livelli circolanti del marcatore tumorale CA 125 in pazienti con scompenso cardiaco cronico:relazione con la classe NYHA, i parametri ecocardiografici e variazioni indotte dalla terapia. 350
Il genotipo DD per il gene dell’enzima di conversione dell’angiotensina identifica i pazienti con insufficienza cardiaca che possono beneficiare di dosi medio elevate di ACE inibitori. 329
Valutazione dell’indice di performance miocardica (MPI) del ventricolo destro con studio eco-doppler in pazienti affetti da insufficienza cardiaca. 312
Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial) 311
Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance 300
I polimorfismi Arg16Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca 247
Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. 244
Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study 229
I polimorfismi Arg16 Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca. 227
L’ indice di performance miocardica ( MPI ) è un importante indicatore prognostico nei pazienti affetti da insufficienza cardiaca cronica. 219
Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. 215
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 196
Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold 195
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. 183
The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. 182
Determinazione dell’equilibrio simpato-vagale attraverso l’analisi spettrale della variabilità della frequenza cardiaca in pazienti con insufficienza cardiaca di diverso grado di severità. 180
Valvola aortica quadricuspide asintomatica : un caso clinico. 179
Efficacia di un nuovo diuretico, la muzolimina, in pazienti con insufficienza cardiaca. 177
Fattori di rischio ed “epidemiologia inversa” nei pazienti con insufficienza cardiaca. 175
A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. 175
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: Findings from the ASTRONAUT trial 172
Serum levels of different tumoral markers in patients with congestive heart failure. 161
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review 160
Acute heart failure syndromes: assessment and reconstructing the heart. 155
A rationale for the use of BETA-blockers as standard treatment for heart failure 153
Are Beta-1 and alpha2c-adrenergic receptor polymorphisms associated with an increased risk of heart failure in Caucasian subjects: results of a case-control study 153
Acute hemodynamic effects of the two dopaminergic agonists ibopamine and dihydroergotamine, a comparison with the parent compound. 151
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial) 150
Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists 150
Raised homocystein plasma concentration in patients with heart failure: Clinical significance 149
Beta- adrenergic receptors polymorphisms and response to CRT 148
Prognostic Value of Serial Clinical, Laboratory and Ecocardiographic Tests in Ambulatory Patients with Chronic Heart Failure 147
The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T 146
Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients with Chronic Heart Failure 146
Clinical trials update from the World Congress of Cardiology 2006. 144
Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. 144
Anemia and heart failure : a cause of progression or only a consequence? 143
Effects of aldosterone blockers on left ventricular function and remodeling in patients with mild-moderate chronic heart failure. 141
Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. 140
Clinical significance of Beta-adrenergic receptor polymorphisms in the patients with chronic heart failure 140
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial 137
The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. 136
Cardiovascular and non cardiovascular comorbidities in patients with chronic heart failure. 136
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 135
Asse cuore-rene nell’iperteso cardiopatico. 132
Acute and chronic effects of nisoldipine in patients with chronic heart failure. 132
Nutritional Supplementation with Amino Acids in Ambulatory Patients with Idiophatic Dilatated Cardiomyophaty 132
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial 131
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial) 129
Acute antianginal efficacy and duration of action of isosorbide 2-mononitrate. 128
Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction 128
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. 128
A randomized comparison of the effects of metoprolol and carvedilol on the hemodynamics and functional capacity of patients with heart failure. 127
Influence of the angiotensin-converting enzyme genotype on the response to the beta-blocker therapy and the prognosis of the patients with chronic heart failure. 127
A randomized double blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant hypertension. Ca+ Nicardipine. Selected reports from the worldwide literature. 126
A Current treatment in acute and chronic cardio-renal syndrome. 126
Response to the letter of Hester Den Ruijter and Ruben Coronel regarding the article "the role of n-3 pufas in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy" 126
Independent role of resting heart rate at discharge as a predictor of mortality after hospitalisation for acute heart failure. 125
Six-year prognosis of diabetic patients with coronary artery disease. 125
Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. 125
Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. 124
Ruolo prognostico della fibrinogemia in pazienti diabetici ricoverati per sindrome coronarica acuta. 123
1Beta-2 adrenergic receptors gene polymorphisms influence the effects of carvedilol in the patients with heart failure. 123
Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. 123
Redefining biomarkers in heart failure 122
Mediterranean diet impact on cardiovascular diseases: A narrative review 122
Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies 121
Rest and exercise effects of the acute and chronic administration of nisoldipine in patients with heart failure. 120
Different prognostic values of clinical and metabolic parameters in ischaemic diabetic patients with preserved/impaired left ventricular function. 120
Significato prognostico indipendente della frequenza cardiaca a riposo alla dimissione come predittore di mortalità in pazienti ricoverati per insufficienza cardiaca acuta. 120
Acute hemodynamic and neurohumoral effects of the oral dopamine derivative ibopamine in patients with heart failure. 119
A new dopamine derivative, ibopamine, in the chronic treatment of heart failure: one year follow-up. 119
Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score 119
Bilancia simpatovagale ed eziologia dell’insufficienza cardiaca: valutazione mediante analisi spettrale della variabilità della frequenza cardiaca. 118
Abnormal hemodynamics and ventilatory response to exercise may identify chronic heart failure patients at high risk despite long term beta-blocker treatment. 118
Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report 118
Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial 118
Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure 118
Maximal and submaximal exercise testing in heart failure. 118
Ibopamine treatment in dopamine dependent heart failure: purpose of a new treatment scheme. 117
Role of fluid retention in patients hospitalised for acute heart failure. 117
Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly? 117
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion 117
Weight loss favorably affects the cardiac sympatho-vagal balance of the obese patients: results of power spectral analysis of heart rate variability. 116
Beta-1 adrenoceptor gene polimorphism in heart failure: clinical and prognostic significance in female patients. 116
Beta-1 adrenergic receptor gene polimorphism in heart failure: a gender specific clinical and prognostic role? 116
Valutazione emodinamica e neurormonale di tre agenti dopaminergici in pazienti con grave insufficienza cardiaca. 115
Biventricular cardiac resynchronization in moderate-to-severe heart failure: Analysis of hospital costs and clinical effectiveness (Brescia study) 115
Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. 115
Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms. 115
Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure 115
Clinical significance of beta-adrenergic receptor polymorphisms in the patients with chronic heart failure. 114
Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. 114
Physiopathology of sudden cardiac death. 113
Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. 113
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions 113
Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. 112
Totale 16.366
Categoria #
all - tutte 342.181
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 342.181


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.601 0 0 0 0 0 1.054 231 1.058 1.662 521 921 154
2021/20225.011 136 1.082 50 343 85 253 151 371 292 647 523 1.078
2022/20235.509 852 63 48 516 513 1.620 16 565 855 44 194 223
2023/20244.104 333 101 174 234 145 740 121 110 1.207 60 99 780
2024/202510.958 65 57 93 1.249 1.485 762 930 452 1.169 568 2.476 1.652
2025/202611.767 1.917 3.326 1.497 2.917 1.674 436 0 0 0 0 0 0
Totale 67.826